Association of mild kidney dysfunction with diastolic dysfunction and heart failure with preserved ejection fraction.
Heart failure with preserved ejection fraction
Kidney dysfunction
Left ventricular diastolic dysfunction
Risk factors
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
13
07
2023
received:
08
12
2022
accepted:
10
08
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
We aim to investigate the association between kidney dysfunction and left ventricular diastolic dysfunction parameters and heart failure with preserved ejection fraction (HFpEF) and whether this is sex-specific. We included participants from the HELPFul observational study. Outpatient clinical care data, including echocardiography, and an expert panel judgement on HFpEF was collected. Estimated glomerular filtration rate (eGFR) was calculated by creatinine and cystatin C without race. The association between eGFR with E/e', left ventricular mass index, relative wall thickness, and stage C/D heart failure was tested by multivariable adjusted regression models, stratified by sex, reporting odds ratios and 95% confidence intervals (95% confidence interval). We analysed 880 participants, mean age 62.9 (standard deviation: 9.3) years, 69% female. Four hundred six participants had mild (37.6%) kidney dysfunction (eGFR: 60-89 mL/min/1.73 m Both mild and moderate kidney dysfunction are independently associated with left ventricular diastolic dysfunction parameters and HFpEF. This association is independent of sex and strongest for moderate kidney dysfunction. Considering mild-to-moderate kidney dysfunction as risk factor for HFpEF may help identify high-risk groups benefiting most from early intervention.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Dutch Heart Foundation
ID : 2013T084
Organisme : Dutch CardioVascular Alliance
ID : 2020B008 RECONNEXT
Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-1356. doi:10.1002/ejhf.1858
de Boer AR, Vaartjes I, Gohar A, Valk MJM, Brugts JJ, Boonman-de Winter LJM, et al. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: An observational study. ESC Heart Fail 2022;9:363-372. doi:10.1002/ehf2.13742
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259. doi:10.1056/NEJMoa052256
Payne J, Sharma S, de Leon D, Lu JL, Alemu F, Balogun RA, et al. Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2012;27:694-700. doi:10.1093/ndt/gfr282
Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Su HM, et al. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Exp Diabetes Res 2012;2012:789325. doi:10.1155/2012/789325
Wu IW, Hung MJ, Chen YC, Hsu HJ, Cherng WJ, Chang CJ, et al. Ventricular function and all-cause mortality in chronic kidney disease patients with angiographic coronary artery disease. J Nephrol 2010;23:181-188.
Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 2007;13:422-430. doi:10.1016/j.cardfail.2007.03.011
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-1996. doi:10.1016/j.jacc.2005.11.084
Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007;18:1307-1315. doi:10.1681/ASN.2006101159
Ricardo AC, Yang W, Sha D, Appel LJ, Chen J, Krousel-Wood M, et al. Sex-related disparities in CKD progression. J Am Soc Nephrol 2019;30:137-146. doi:10.1681/ASN.2018030296
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591-602. doi:10.1038/nrcardio.2017.65
United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2019.
Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: A population-based study. Circ Heart Fail 2012;5:144-151. doi:10.1161/CIRCHEARTFAILURE.110.959668
McCullough PA, Kellum JA, Haase M, Müller C, Damman K, Murray PT, et al. Pathophysiology of the cardiorenal syndromes: Executive summary from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:82-98. doi:10.1159/000349966
Haase M, Müller C, Damman K, Murray PT, Kellum JA, Ronco C, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: Workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:99-116. doi:10.1159/000349969
Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: Workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:117-136. doi:10.1159/000349968
Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 2005;26:11-17. doi:10.1093/eurheartj/ehi020
Bagshaw SM, Hoste EA, Braam B, Briguori C, Kellum JA, McCullough PA, et al. Cardiorenal syndrome type 3: Pathophysiologic and epidemiologic considerations. Contrib Nephrol 2013;182:137-157. doi:10.1159/000349971
Tumlin JA, Costanzo MR, Chawla LS, Herzog CA, Kellum JA, McCullough PA, et al. Cardiorenal syndrome type 4: Insights on clinical presentation and pathophysiology from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:158-173. doi:10.1159/000349972
Mehta RL, Rabb H, Shaw AD, Singbartl K, Ronco C, McCullough PA, et al. Cardiorenal syndrome type 5: Clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:174-194. doi:10.1159/000349970
Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014;35:455-469. doi:10.1093/eurheartj/eht386
Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34:1424-1431. doi:10.1093/eurheartj/eht066
Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840-849. doi:10.1093/eurheartj/ehx721
Bobenko A, Duvinage A, Mende M, Holzendorf V, Nolte K, Herrmann-Lingen C, et al. Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction. Int J Cardiol Heart Vasc 2020;28:100525. doi:10.1016/j.ijcha.2020.100525
Pugliese NR, de Biase N, Gargani L, Mazzola M, Conte L, Fabiani I, et al. Predicting the transition to and progression of heart failure with preserved ejection fraction: A weighted risk score using bio-humoural, cardiopulmonary, and echocardiographic stress testing. Eur. J Prev Cardiol 2020;28:zwaa129. doi:10.1159/000349970
Caballero L, Saura D, García-Lara J, Oliva MJ, Pinar E, González-Carrillo J, et al. Influence of aortic regurgitation after TAVI on left ventricular filling pattern. Eur J Clin Invest 2015;45:18-26. doi:10.1111/eci.12374
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. doi:10.1001/jama.289.2.194
Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012;23:1725-1734. doi:10.1681/ASN.2012020145
Kloch-Badelek M, Kuznetsova T, Sakiewicz W, Tikhonoff V, Ryabikov A, González A, et al. Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovasc Ultrasound 2012;10:10. doi:10.1186/1476-7120-10-10
Rasmussen-Torvik LJ, Colangelo LA, Lima JAC, Jacobs DR, Rodriguez CJ, Gidding SS, et al. Prevalence and predictors of diastolic dysfunction according to different classification criteria: The coronary artery risk development in young in adults study. Am J Epidemiol 2017;185:1221-1227. doi:10.1093/aje/kww214
Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 2010;96:528-532. doi:10.1136/hrt.2009.177980
Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, et al. Natriuretic peptide-based screening and collaborative care for heart failure: The STOP-HF randomized trial. JAMA 2013;310:66-74. doi:10.1001/jama.2013.7588
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-1461. doi:10.1056/NEJMoa2107038
Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, et al. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol 2015;200:15-19. doi:10.1016/j.ijcard.2015.07.038
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-1098. doi:10.1056/NEJMoa2206286
Valstar GB, Bots SH, Groepenhoff F, Gohar A, Rutten FH, Leiner T, et al. Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with preserved ejection fraction in patients at risk for cardiovascular disease: Rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic. BMJ Open 2019;9:e028408. doi:10.1136/bmjopen-2018-028408
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385:1737-1749. doi:10.1056/NEJMoa2102953
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314. doi:10.1016/j.echo.2016.01.011
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC) Eur Heart J 2019;40:3297-3317. doi:10.1093/eurheartj/ehz641
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861-870. doi:10.1161/CIRCULATIONAHA.118.034646
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation 2017;136:e137-e161. doi:10.1161/CIR.0000000000000509
Jain A, Scott C, Chen HH. The renal-cardiac connection in subjects with preserved ejection fraction: A population based study. ESC Heart Fail 2017;4:266-273. doi:10.1002/ehf2.12143
Nerpin E, Ingelsson E, Risérus U, Sundström J, Andren B, Jobs E, et al. The association between glomerular filtration rate and left ventricular function in two independent community-based cohorts of elderly. Nephrol Dial Transplant 2014;29:2069-2074. doi:10.1093/ndt/gfu199
Agarwal S, Thohan V, Shlipak MG, Lima J, Bluemke DA, Siscovick D, et al. Association between cystatin C and MRI measures of left ventricular structure and function: Multi-ethnic study of atherosclerosis. Int J Nephrol 2011;2011:153868. doi:10.4061/2011/153868
Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: Data from the heart and soul study. J Card Fail 2006;12:601-607. doi:10.1016/j.cardfail.2006.07.005
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. doi:10.1159/000180580
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29. doi:10.1056/NEJMoa1114248
Agarwal R, Light RP. Determinants and prognostic significance of electrocardiographic left ventricular hypertrophy criteria in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:528-536. doi:10.2215/CJN.07770910
Patel RK, Oliver S, Mark PB, Powell JR, McQuarrie EP, Traynor JP, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol 2009;4:1477-1483. doi:10.2215/CJN.03350509
Masugata H, Senda S, Goda F, Yamagami A, Okuyama H, Kohno T, et al. Echocardiographic assessment of the cardio-renal connection: Is left ventricular hypertrophy or diastolic function more closely correlated with estimated glomerular filtration rate in patients with cardiovascular risk factors? Clin Exp Hypertens 2010;32:113-120. doi:10.3109/10641960902993145
Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens 2009;27:633-641. doi:10.1097/HJH.0b013e3283220ecd
Shah AM, Lam CS, Cheng S, Verma A, Desai AS, Rocha RA, et al. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens 2011;29:1829-1836. doi:10.1097/HJH.0b013e32834a4d38
Eikendal ALM, Gohar A, Rutten FH, Bots ML, Appelman Y, Hofstra L, et al. Sex-specific relations of cardiovascular risk factors with left ventricular diastolic dysfunction/heart failure with preserved ejection fraction are underreported: A call for action. J Card Fail 2018;24:412-414. doi:10.1016/j.cardfail.2018.03.001
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838-1847. doi:10.1056/NEJMoa2021372
Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: A meta-analysis of propensity score analyses. Int J Cardiol 2016;214:301-306. doi:10.1016/j.ijcard.2016.03.186
Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, et al. Risk for incident heart failure: A subject-level meta-analysis from the heart “OMics“ in AGEing (HOMAGE) study. J Am Heart Assoc 2017;6:e005231. doi:10.1161/JAHA.116.005231
Dini FL, Demmer RT, Simioniuc A, Morrone D, Donati F, Guarini G, et al. Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure. Eur J Heart Fail 2012;14:287-294. doi:10.1093/eurjhf/hfr176
Gama RM, Clery A, Griffiths K, Heraghty N, Peters AM, Palmer K, et al. Estimated glomerular filtration rate equations in people of self-reported black ethnicity in the United Kingdom: Inappropriate adjustment for ethnicity may lead to reduced access to care. PLoS ONE 2021;16:e0255869. doi:10.1371/journal.pone.0255869
Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to estimate kidney function. JAMA 2019;322:113-114. doi:10.1001/jama.2019.5774
Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: A simultaneous invasive-echocardiographic study. Circulation 2017;135:825-838. doi:10.1161/CIRCULATIONAHA.116.024822
Faxen UL, Venkateshvaran A, Shah SJ, Lam CSP, Svedlund S, Saraste A, et al. Generalizability of HFA-PEFF and H2FPEF diagnostic algorithms and associations with heart failure indices and proteomic biomarkers: Insights from PROMIS-HFpEF. J Card Fail 2021;27:756-765. doi:10.1016/j.cardfail.2021.02.005
Bertens LC, Broekhuizen BD, Naaktgeboren CA, Rutten FH, Hoes AW, van Mourik Y, et al. Use of expert panels to define the reference standard in diagnostic research: A systematic review of published methods and reporting. PLoS Med 2013;10:e1001531. doi:10.1371/journal.pmed.1001531